Age-related macular degeneration is a major cause of visual loss in the elderly. As many as 200 million individuals are affected globally.
AMD is usually classified as early, intermediate or late. Late AMD represents about one in 10 patients with AMD and includes wet, or exudative, AMD and geographic atrophy. Each affects about 5 million patients in the U.S. The therapy for wet AMD is well established using intravitreal anti-VEGF therapy.
Long-term intravitreal anti-VEGF therapy for wet AMD can itself result in geographic atrophy. In geographic atrophy, there is complete (Read more...)